Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug–drug interactions during acenocoumarol treatment

Impact of theCYP2C8*3polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone

(2012) Christina L. Aquilante et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Oral Anticoagulant Therapy

(2012) Walter Ageno et al.   CHEST

Evidence-Based Management of Anticoagulant Therapy

(2012) Anne Holbrook et al.   CHEST

Identification and weighting of the most critical “real-life” drug–drug interactions with acenocoumarol in a tertiary care hospital

(2012) L. Gschwind et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Adverse drug reactions caused by drug–drug interactions in elderly outpatients: a prospective cohort study

(2012) Paulo Roque Obreli-Neto et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

A clinically significant interaction between warfarin and simvastatin is unique to carriers of theCYP2C9*3allele

(2012) Marine L Andersson et al.   PHARMACOGENOMICS

Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy

(2011) I. Y. Gong et al.   BLOOD

Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization Studies

(2009) Santiago Rodriguez et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients

(2009) Milka Hauta-Aho et al.   ANNALS OF MEDICINE

Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements

(2009) Janne Cadamuro et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The largest prospective warfarin-treated cohort supports genetic forecasting

(2008) M. Wadelius et al.   BLOOD

Pharmacogenetics of Oral Anticoagulants

(2008) Simone Stehle et al.   CLINICAL PHARMACOKINETICS

The Role of Cytochrome P2C19 in R-warfarin Pharmacokinetics and its Interaction With Omeprazole

(2008) Tsukasa Uno et al.   THERAPEUTIC DRUG MONITORING